Traws Pharma (NASDAQ:TRAW) Upgraded by LADENBURG THALM/SH SH to “Strong-Buy” Rating

LADENBURG THALM/SH SH upgraded shares of Traws Pharma (NASDAQ:TRAW) to a strong-buy rating in a research note released on Friday,Zacks.com reports.

Several other research firms also recently commented on TRAW. HC Wainwright initiated coverage on Traws Pharma in a research note on Wednesday, December 3rd. They issued a “buy” rating and a $8.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Traws Pharma in a research note on Monday, December 22nd. Zacks Research raised Traws Pharma to a “hold” rating in a research report on Thursday, December 4th. Finally, Wall Street Zen lowered Traws Pharma from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Traws Pharma Stock Performance

NASDAQ TRAW opened at $2.11 on Friday. The company has a market capitalization of $16.86 million, a PE ratio of 0.02 and a beta of 1.66. Traws Pharma has a 52-week low of $0.97 and a 52-week high of $8.61. The company has a 50-day simple moving average of $1.91 and a 200 day simple moving average of $1.94.

Traws Pharma (NASDAQ:TRAW) last released its earnings results on Thursday, November 13th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($9.16) by $8.82. Traws Pharma had a net margin of 3,028.25% and a negative return on equity of 2,883.04%.

Hedge Funds Weigh In On Traws Pharma

An institutional investor recently raised its position in Traws Pharma stock. Two Sigma Investments LP lifted its stake in shares of Traws Pharma, Inc. (NASDAQ:TRAW) by 37.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,018 shares of the company’s stock after purchasing an additional 5,955 shares during the quarter. Two Sigma Investments LP owned 0.31% of Traws Pharma worth $41,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.